This website is intended for US Healthcare Professionals.

Externally Sponsored
Research Program​

At Arvinas, we are dedicated to advancing scientific understanding and improving patient care through our Externally Sponsored Research (ESR) program. We provide support for Investigator-Sponsored Research (ISR) and Research Collaborations aligned with our medical and scientific interests.

Areas of Interest

Arvinas will consider ESR proposals in the following areas of interest: 

Vepdegestrant

Vepdegestrant is being co-developed with Pfizer. ISR proposals in the United States will only be accepted by Arvinas.  

ER+ Metastatic Breast Cancer (MBC) 2L+ 

  • Novel combinations with strong rationale and/or preclinical data
  • Monotherapy and/or combination approaches to inform response, resistance, and treatment decisions (e.g. biomarker and/or imaging studies)
  • Sequencing studies
  • Specific patient populations, especially those under/not represented in registrational studies

 

ER+ BC

  • Neoadjuvant studies evaluating novel combinations and/or translational endpoints may be considered

 

Other Disease Areas

  • Signal-seeking studies of vepdegestrant in other HR+ malignancies

 

Out of Scope

  • Adjuvant BC

Process Outline

We recommend submission of Investigator Sponsored Research support requests at least 9 months prior to planned research initiation. Please review the following information carefully to ensure all requirements are met, as this will facilitate a timely review.

  • Type of support requested (product, funding, or both) 
  • Source(s) of other funding not provided by Arvinas, if applicable 
  • Name, curriculum vitae, and contact information of proposed Investigator 
  • Study Title 
  • Rationale  
  • Objectives and Endpoints 
  • Outline of study design 
  • Timeline 
  • Preliminary budget 
  • Publication plan 

Application and Questions

To submit an ESR proposal, please email externalresearch@arvinas.com. If you have any questions, please email us at externalresearch@arvinas.com or contact your regional Medical Science Liaison (MSL).  

For assistance in identifying the MSL for your territory, please click here to use our MSL locator.  

Arvinas Oncology Medical

You are now leaving arvinasmedical.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.